Literature DB >> 25006127

Mouse models in the study of chronic lymphocytic leukemia pathogenesis and therapy.

Giorgia Simonetti1, Maria Teresa Sabrina Bertilaccio2, Paolo Ghia3, Ulf Klein4.   

Abstract

Mouse models that recapitulate human malignancy are valuable tools for the elucidation of the underlying pathogenetic mechanisms and for preclinical studies. Several genetically engineered mouse models have been generated, either mimicking genetic aberrations or deregulated gene expression in chronic lymphocytic leukemia (CLL). The usefulness of such models in the study of the human disease may potentially be hampered by species-specific biological differences in the target cell of the oncogenic transformation. Specifically, do the genetic lesions or the deregulated expression of leukemia-associated genes faithfully recapitulate the spectrum of lymphoproliferations in humans? Do the CLL-like lymphoproliferations in the mouse have the phenotypic, histological, genetic, and clinical features of the human disease? Here we compare the various CLL mouse models with regard to disease phenotype, penetrance, and severity. We discuss similarities and differences of the murine lymphoproliferations compared with human CLL. We propose that the Eμ-TCL1 transgenic and 13q14-deletion models that have been comprehensively studied at the levels of leukemia phenotype, antigen-receptor repertoire, and disease course show close resemblance to the human disease. We conclude that modeling CLL-associated genetic dysregulations in mice can provide important insights into the molecular mechanisms of disease pathogenesis and generate valuable tools for the development of novel therapies.
© 2014 by The American Society of Hematology.

Entities:  

Mesh:

Year:  2014        PMID: 25006127     DOI: 10.1182/blood-2014-05-577122

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  31 in total

1.  Oxidative stress as candidate therapeutic target to overcome microenvironmental protection of CLL.

Authors:  Deyan Yordanov Yosifov; Irina Idler; Nupur Bhattacharya; Michaela Reichenzeller; Viola Close; Daria Ezerina; Annika Scheffold; Billy Michael Chelliah Jebaraj; Sabrina Kugler; Johannes Bloehdorn; Jasmin Bahlo; Sandra Robrecht; Barbara Eichhorst; Kirsten Fischer; Anja Weigel; Hauke Busch; Peter Lichter; Hartmut Döhner; Tobias P Dick; Stephan Stilgenbauer; Daniel Mertens
Journal:  Leukemia       Date:  2019-07-12       Impact factor: 11.528

2.  Mechanisms of PD-L1/PD-1-mediated CD8 T-cell dysfunction in the context of aging-related immune defects in the Eµ-TCL1 CLL mouse model.

Authors:  Fabienne McClanahan; John C Riches; Shaun Miller; William P Day; Eleni Kotsiou; Donna Neuberg; Carlo M Croce; Melania Capasso; John G Gribben
Journal:  Blood       Date:  2015-05-15       Impact factor: 22.113

3.  Integrated Cellular and Plasma Proteomics of Contrasting B-cell Cancers Reveals Common, Unique and Systemic Signatures.

Authors:  Harvey E Johnston; Matthew J Carter; Kerry L Cox; Melanie Dunscombe; Antigoni Manousopoulou; Paul A Townsend; Spiros D Garbis; Mark S Cragg
Journal:  Mol Cell Proteomics       Date:  2017-01-04       Impact factor: 5.911

4.  EBI2 overexpression in mice leads to B1 B-cell expansion and chronic lymphocytic leukemia-like B-cell malignancies.

Authors:  Kristine Niss Arfelt; Line Barington; Tau Benned-Jensen; Valentina Kubale; Alexander L Kovalchuk; Viktorija Daugvilaite; Jan Pravsgaard Christensen; Allan Randrup Thomsen; Kristoffer L Egerod; Maria R Bassi; Katja Spiess; Thue W Schwartz; Hongsheng Wang; Herbert C Morse; Peter J Holst; Mette M Rosenkilde
Journal:  Blood       Date:  2016-12-21       Impact factor: 22.113

5.  Anti-leukemic activity of microRNA-26a in a chronic lymphocytic leukemia mouse model.

Authors:  L D'Abundo; E Callegari; A Bresin; A Chillemi; B K Elamin; P Guerriero; X Huang; E Saccenti; E M A A Hussein; F Casciano; P Secchiero; G Zauli; G A Calin; G Russo; L J Lee; C M Croce; G Marcucci; S Sabbioni; F Malavasi; M Negrini
Journal:  Oncogene       Date:  2017-08-07       Impact factor: 9.867

6.  Exosomes released by chronic lymphocytic leukemia cells induce the transition of stromal cells into cancer-associated fibroblasts.

Authors:  Jerome Paggetti; Franziska Haderk; Martina Seiffert; Bassam Janji; Ute Distler; Wim Ammerlaan; Yeoun Jin Kim; Julien Adam; Peter Lichter; Eric Solary; Guy Berchem; Etienne Moussay
Journal:  Blood       Date:  2015-06-22       Impact factor: 22.113

7.  Functional Differences between IgM and IgD Signaling in Chronic Lymphocytic Leukemia.

Authors:  Elisa Ten Hacken; Mariela Sivina; Ekaterina Kim; Susan O'Brien; William G Wierda; Alessandra Ferrajoli; Zeev Estrov; Michael J Keating; Thomas Oellerich; Cristina Scielzo; Paolo Ghia; Federico Caligaris-Cappio; Jan A Burger
Journal:  J Immunol       Date:  2016-08-17       Impact factor: 5.422

8.  Microenvironment-induced CD44v6 promotes early disease progression in chronic lymphocytic leukemia.

Authors:  Julia C Gutjahr; Eva Szenes; Lisa Tschech; Daniela Asslaber; Michaela Schlederer; Simone Roos; Xiaobing Yu; Tamara Girbl; Christina Sternberg; Alexander Egle; Fritz Aberger; Ronen Alon; Lukas Kenner; Richard Greil; Veronique Orian-Rousseau; Tanja N Hartmann
Journal:  Blood       Date:  2018-01-19       Impact factor: 22.113

Review 9.  The long journey of TCL1 transgenic mice: lessons learned in the last 15 years.

Authors:  Yuri Pekarsky; Alessandra Drusco; Prasanthi Kumchala; Carlo M Croce; Nicola Zanesi
Journal:  Gene Expr       Date:  2015

10.  The PTPROt tyrosine phosphatase functions as an obligate haploinsufficient tumor suppressor in vivo in B-cell chronic lymphocytic leukemia.

Authors:  J Wakim; E Arman; S Becker-Herman; M P Kramer; E Bakos; I Shachar; A Elson
Journal:  Oncogene       Date:  2017-02-06       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.